Table 3.
Final model for overall survival in the development cohort (no covariates were removed from the full model)
| HR | 2.5% | 97.5% | P | |
|---|---|---|---|---|
| Age | 1.03 | 1.02 | 1.04 | <0.01 |
| Gender, Female (ref) | ||||
| Male | 1.19 | 0.96 | 1.47 | 0.12 |
| HPV–/p16– (ref) | ||||
| HPV–/p16+ | 1.01 | 0.63 | 1.64 | 0.96 |
| HPV+/p16– | 0.75 | 0.51 | 1.10 | 0.14 |
| HPV+/p16+ | 0.39 | 0.26 | 0.58 | <0.01 |
| Smoking, Current (ref) | ||||
| Former | 0.62 | 0.49 | 0.77 | <0.01 |
| Never | 0.54 | 0.38 | 0.77 | <0.01 |
| UICC8 I (ref) | ||||
| UICC8 II | 0.97 | 0.66 | 1.44 | 0.88 |
| UICC8 III | 1.46 | 0.92 | 2.31 | 0.11 |
| UICC8 IV | 1.27 | 0.63 | 2.56 | 0.51 |
| T1 (ref) | ||||
| T2 | 1.39 | 1.02 | 1.87 | 0.03 |
| T3 | 1.89 | 1.34 | 2.67 | <0.01 |
| T4 | 2.72 | 1.79 | 4.14 | <0.01 |
| N0 (ref) | ||||
| N1 | 1.08 | 0.81 | 1.43 | 0.59 |
| N2 | 1.40 | 0.94 | 2.08 | 0.10 |
| N3 | 1.98 | 1.29 | 3.04 | <0.01 |
| M0 (ref) | ||||
| M1 | 2.28 | 1.28 | 4.08 | 0.01 |